Abstract |
Cytarabine and thioguanine therapy for acute myelomonocytic leukemia initiated in the tenth week of pregnancy (with the addition of vincristine and rubidomycin at 17 weeks) led to a short complete remission of the leukemia in a 24-year-old primigravida. This is the first case to be reported in which cytarabine was administered in the first trimester and a prostaglandin termination of pregnancy performed at 20 weeks produced an apparently normal fetus. A review of the literature suggests a slightly less than 50% chance of producing a live healthy baby if acute myelogenous leukemia is diagnosed in the first half of pregnancy, with materna mortality approaching 100% by six months postpartum. Current therapy may improve these figures.
|
Authors | J S Lilleyman, A S Hill, K J Anderton |
Journal | Cancer
(Cancer)
Vol. 40
Issue 3
Pg. 1300-3
(Sep 1977)
ISSN: 0008-543X [Print] United States |
PMID | 332324
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Teratogens
- Cytarabine
- Vincristine
- Thioguanine
- Daunorubicin
|
Topics |
- Abortion, Therapeutic
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cytarabine
(therapeutic use)
- Daunorubicin
(therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Infant Mortality
- Infant, Newborn
- Leukemia, Myeloid
(drug therapy, mortality)
- Leukemia, Myeloid, Acute
(complications)
- Pregnancy
- Pregnancy Complications, Hematologic
(drug therapy, mortality)
- Pregnancy Trimester, First
- Pregnancy Trimester, Second
- Risk
- Teratogens
- Thioguanine
(therapeutic use)
- Vincristine
(therapeutic use)
|